Assenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,856 shares of the biotechnology company’s stock after buying an additional 49,050 shares during the quarter. Assenagon Asset Management S.A. owned about 0.91% of Enanta Pharmaceuticals worth $1,109,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ENTA. Rhumbline Advisers lifted its stake in shares of Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after buying an additional 1,548 shares in the last quarter. American Century Companies Inc. raised its holdings in Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 7,287 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after acquiring an additional 18,003 shares in the last quarter. US Bancorp DE boosted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares during the period. Finally, Quest Partners LLC boosted its stake in shares of Enanta Pharmaceuticals by 65.0% in the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 7,535 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 13.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ENTA. Robert W. Baird lowered their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. HC Wainwright reduced their price objective on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $5.53 on Friday. The stock has a market capitalization of $117.18 million, a PE ratio of -1.01 and a beta of 0.56. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.71 and a 1-year high of $17.80. The business has a 50 day simple moving average of $6.73 and a two-hundred day simple moving average of $10.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same period last year, the business posted ($1.33) earnings per share. On average, analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.93 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.